Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle

References

1. 1.↵
   2. Wang J,
   3. Sun JW,
   4. Liu LN,
   5. Flies DB,
   6. Nie XX,
   7. Toki M, et al.

   Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25:656–66.

   OpenUrlCrossRefPubMed
2. 2.↵
   2. Sanmamed MF,
   3. Chen LP.

   A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175:313–26.

   OpenUrlCrossRefPubMed
3. 3.↵
   2. Kantoff PW,
   3. Higano CS,
   4. Shore ND,
   5. Berger ER,
   6. Small EJ,
   7. Penson DF, et al.

   Sipuleucel-t immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   2. Rosenberg SA.

   IL-2: The first effective immunotherapy for human cancer. J Immunol. 2014;192:5451–8.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   2. Chen LP,
   3. Han X.

   Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125:3384–91.

   OpenUrlCrossRefPubMed
6. 6.↵
   2. Gangadhar TC,
   3. Vonderheide RH.

   Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol. 2014;11:91–9.

   OpenUrlCrossRefPubMed
7. 7.↵
   2. Dong H,
   3. Strome SE,
   4. Salomao DR,
   5. Tamura H,
   6. Hirano F,
   7. Flies DB, et al.

   Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   2. Zou WP,
   3. Wolchok JD,
   4. Chen LP.

   PD-L1(B7-H1) and pd-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4.

   OpenUrlFREE Full Text
9. 9.↵
   2. Xu XL,
   3. Huang ZY,
   4. Zheng L,
   5. Fan Y.

   The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer. Int J Cancer. 2018;142:2344–54.

   OpenUrlCrossRef
10. 10.↵
    2. Taube JM,
    3. Anders RA,
    4. Young GD,
    5. Xu HY,
    6. Sharma R,
    7. McMiller TL, et al.

    c. Sci Transl Med. 2012;4:127ra37.

    OpenUrlAbstract/FREE Full Text
11. 11.
    2. Sznol M,
    3. Chen LP.

    Antagonist antibodies to PD-1 and B7-H1(PD-L1) in the treatment of advanced human cancer. Clin Cancer Res. 2013;19:1021–34.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    2. Zhang Y,
    3. Chen LP.

    Classification of advanced human cancers based on tumor immunity in the microenvironment (TIME) for cancer immunotherapy. JAMA Oncol. 2016;2:1403–4.

    OpenUrl
13. 13.↵
    2. Wang J,
    3. Sanmamed MF,
    4. Datar I,
    5. Su TT,
    6. Ji L,
    7. Sun JW, et al.

    Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019;176:334–47.e12.

    OpenUrlCrossRefPubMed
14. 14.↵
    2. Gajewski TF,
    3. Schreiber H,
    4. Fu YX.

    Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–22.

    OpenUrlCrossRefPubMed
15. 15.↵
    2. Mittal D,
    3. Gubin MM,
    4. Schreiber RD,
    5. Smyth MJ.

    New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25.

    OpenUrlCrossRefPubMed
16. 16.↵
    2. Crocker PR,
    3. Paulson JC,
    4. Varki A.

    Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7:255–66.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    2. Angata T,
    3. Tabuchi Y,
    4. Nakamura K,
    5. Nakamura M.

    Siglec-15: an immune system siglec conserved throughout vertebrate evolution. Glycobiology. 2007;17:838–46.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    2. Kameda Y,
    3. Takahata M,
    4. Komatsu M,
    5. Mikuni S,
    6. Hatakeyama S,
    7. Shimizu T, et al.

    Siglec-15 regulates osteoclast differentiation by modulating rankl-induced phosphatidylinositol 3-kinase/akt and erk pathways in association with signaling adaptor DAP12. J Bone Miner Res. 2013;28:2463–75.

    OpenUrlCrossRefPubMed
19. 19.↵
    2. Schalper KA,
    3. Carvajal-Hausdorf D,
    4. McLaughlin J,
    5. Altan M,
    6. Velcheti V,
    7. Gaule P, et al.

    Differential expression and significance of PD-L1, IDO-1, and B7-H4 in human lung cancer. Clin Cancer Res. 2017;23:370–8.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    2. Burugu S,
    3. Dancsok AR,
    4. Nielsen TO.

    Emerging targets in cancer immunotherapy. Semin Cancer Biol. 2018;52:39–52.

    OpenUrlCrossRefPubMed
21. 21.↵
    2. Allard B,
    3. Longhi MS,
    4. Robson SC,
    5. Stagg J.

    The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. 2017;276:121–44.

    OpenUrlCrossRefPubMed